AXSM
Price
$184.79
Change
-$2.56 (-1.37%)
Updated
Feb 4, 02:23 PM (EDT)
Capitalization
9.44B
19 days until earnings call
Intraday BUY SELL Signals
VNDA
Price
$7.65
Change
-$0.40 (-4.97%)
Updated
Feb 4, 03:26 PM (EDT)
Capitalization
475.73M
7 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AXSM vs VNDA

Header iconAXSM vs VNDA Comparison
Open Charts AXSM vs VNDABanner chart's image
Axsome Therapeutics
Price$184.79
Change-$2.56 (-1.37%)
Volume$500
Capitalization9.44B
Vanda Pharmaceuticals
Price$7.65
Change-$0.40 (-4.97%)
Volume$500
Capitalization475.73M
AXSM vs VNDA Comparison Chart in %
View a ticker or compare two or three
VS
AXSM vs. VNDA commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXSM is a Hold and VNDA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (AXSM: $187.35 vs. VNDA: $8.05)
Brand notoriety: AXSM and VNDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AXSM: 133% vs. VNDA: 63%
Market capitalization -- AXSM: $9.44B vs. VNDA: $475.73M
AXSM [@Biotechnology] is valued at $9.44B. VNDA’s [@Biotechnology] market capitalization is $475.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AXSM’s FA Score shows that 1 FA rating(s) are green whileVNDA’s FA Score has 1 green FA rating(s).

  • AXSM’s FA Score: 1 green, 4 red.
  • VNDA’s FA Score: 1 green, 4 red.
According to our system of comparison, both AXSM and VNDA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AXSM’s TA Score shows that 3 TA indicator(s) are bullish while VNDA’s TA Score has 3 bullish TA indicator(s).

  • AXSM’s TA Score: 3 bullish, 5 bearish.
  • VNDA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both AXSM and VNDA are a bad buy in the short-term.

Price Growth

AXSM (@Biotechnology) experienced а -0.36% price change this week, while VNDA (@Biotechnology) price change was +0.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Reported Earning Dates

AXSM is expected to report earnings on Feb 23, 2026.

VNDA is expected to report earnings on Feb 11, 2026.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AXSM($9.45B) has a higher market cap than VNDA($476M). AXSM YTD gains are higher at: 2.579 vs. VNDA (-8.730). VNDA has higher annual earnings (EBITDA): -113.07M vs. AXSM (-213.94M). AXSM has more cash in the bank: 325M vs. VNDA (294M). VNDA has less debt than AXSM: VNDA (10.9M) vs AXSM (219M). AXSM has higher revenues than VNDA: AXSM (561M) vs VNDA (212M).
AXSMVNDAAXSM / VNDA
Capitalization9.45B476M1,984%
EBITDA-213.94M-113.07M189%
Gain YTD2.579-8.730-30%
P/E RatioN/A126.00-
Revenue561M212M265%
Total Cash325M294M111%
Total Debt219M10.9M2,009%
FUNDAMENTALS RATINGS
AXSM vs VNDA: Fundamental Ratings
AXSM
VNDA
OUTLOOK RATING
1..100
104
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
28100
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
3838
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AXSM's Valuation (89) in the Pharmaceuticals Other industry is in the same range as VNDA (91) in the Biotechnology industry. This means that AXSM’s stock grew similarly to VNDA’s over the last 12 months.

AXSM's Profit vs Risk Rating (28) in the Pharmaceuticals Other industry is significantly better than the same rating for VNDA (100) in the Biotechnology industry. This means that AXSM’s stock grew significantly faster than VNDA’s over the last 12 months.

VNDA's SMR Rating (95) in the Biotechnology industry is in the same range as AXSM (100) in the Pharmaceuticals Other industry. This means that VNDA’s stock grew similarly to AXSM’s over the last 12 months.

VNDA's Price Growth Rating (38) in the Biotechnology industry is in the same range as AXSM (38) in the Pharmaceuticals Other industry. This means that VNDA’s stock grew similarly to AXSM’s over the last 12 months.

VNDA's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for AXSM (100) in the Pharmaceuticals Other industry. This means that VNDA’s stock grew significantly faster than AXSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AXSMVNDA
RSI
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
63%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
66%
MACD
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
69%
Declines
ODDS (%)
Bearish Trend 10 days ago
78%
Bearish Trend 10 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
72%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
62%
View a ticker or compare two or three
Interact to see
Advertisement
AXSM
Daily Signal:
Gain/Loss:
VNDA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DHIAX22.530.18
+0.81%
Diamond Hill International Inv
RALIX11.260.02
+0.18%
Lazard Real Assets Instl
MPLAX16.93-0.03
-0.18%
Praxis International Index A
JHIGX36.99-0.07
-0.19%
JHancock International Growth R2
MUERX35.75-0.37
-1.02%
MFS Blended Research Core Equity R1

AXSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, AXSM has been loosely correlated with XENE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AXSM jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AXSM
1D Price
Change %
AXSM100%
+0.79%
XENE - AXSM
39%
Loosely correlated
+1.62%
ALNY - AXSM
38%
Loosely correlated
+3.74%
VNDA - AXSM
36%
Loosely correlated
+4.01%
VANI - AXSM
36%
Loosely correlated
-4.76%
PLRX - AXSM
35%
Loosely correlated
+1.68%
More

VNDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VNDA has been loosely correlated with IVF. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if VNDA jumps, then IVF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VNDA
1D Price
Change %
VNDA100%
+4.01%
IVF - VNDA
40%
Loosely correlated
-6.45%
OLMA - VNDA
37%
Loosely correlated
+1.91%
MGTX - VNDA
37%
Loosely correlated
+2.68%
VCYT - VNDA
36%
Loosely correlated
-1.10%
JAZZ - VNDA
36%
Loosely correlated
-0.27%
More